Skip to content
naulon

Not checkedNot checked for notices yet.

Initial Progression-Free Survival afer Non-First Line TKIs Therapy Potentially Guides Immediate Treatment afer Its Failure in Advanced Non-Small Cell Lung Cancer

Fang Wang, Gui-fang Guo, Hui-juan Qiu and 8 more

Cancer Biology & Medicine · 2012

doi:10.3969/j.issn.2095-3941.2012.01.007 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

<b>Objective</b> The standard therapy after failure of the initial non-first line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment in advanced non-small cell lung cancer (NSCLC) has not yet been established. The aim of the current study was to identify whether the 2<sup>nd</sup> TKI treatment or chemotherapy (paclitaxel-containing or non-paclitaxel regimen) is the appropriate treatment for patients with NSCLC based on the efficacy of the initial TKIs.<br><b>Methods</b> Seventy-two advanced NSCLC patients who had accepted 2<sup>nd</sup> TKIs or chemotherapy immediately after failure of the initial TKIs in non-first line setting from May 1, 2004 to January 31, 2010 at the Sun Yat-sen University Cancer Center were enrolled. The primary endpoint [2<sup>nd</sup> progression-free survival (PFS)] and the second endpoint [overall survival (OS)] were compared among the 2<sup>nd</sup> TKI and chemotherapy groups as well as their subgroups.<br><b>Results</b> (1) Twenty-one patients were treated with 2<sup>nd</sup> TKIs, and 51 patients were administered chemotherapy after failure of the initial non-first line TKI treatment. There was nonsignificant difference in the responses (<i>P</i>=0.900) [2<sup>nd</sup> PFS (<i>P</i>=0.833) and OS (<i>P</i>=0.369)] between the 2<sup>nd</sup> TKI and chemotherapy groups. (2) In the 2<sup>nd</sup> TKI group, 9 patients exhibited PFS≥7 months. The initial TKI treatment group exhibited a longer 2<sup>nd</sup> PFS than the other 12 patients with an initial PFS<7 months (7 months <i>vs</i>. 2 months, <i>P</i>=0.019). However, these groups had nonsignificantly different OS (<i>P</i>=0.369). (3) In the chemotherapy group, patients with PFS<5 months exhibited longer 2<sup>nd</sup> PFS than those with PFS ≥ 5 months in the initial TKI treatment (3 months <i>vs</i>. 2 months, <i>P</i>=0.039). (4) In the chemotherapy group, patients treated with paclitaxel-containing regimen showed longer 2<sup>nd</sup> PFS than those treated with non-paclitaxel regimen (5 months <i>vs</i>. 2.3 months, <i>P</i>=0.043).<br><b>Conclusions</b> Patients with PFS≥7 months or <5 months under the initial TKI treatment potentially benefit from the 2<sup>nd</sup> TKI treatment or chemotherapy immediately after failure of the non-first line TKIs. The paclitaxel-containing regimen may improve the 2<sup>nd</sup> PFS. However, more patient samples are urgently needed to validate these findings.

Abstract licence: CC BY-NC

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.